03:36 AM EST, 11/05/2025 (MT Newswires) -- Soleno Therapeutics ( SLNO ) reported Q3 earnings late Tuesday of $0.47 per diluted share, swinging from a loss of $1.83 a year earlier.

Three analysts polled by FactSet expected $0.07.

Net product revenue for the quarter ended Sept. 30 was $66 million. The company did not report revenue in the same period a year earlier.

Analysts surveyed by FactSet expected $48.1 million.

Between its approval in March and September 30, Soleno received 1,043 patient start forms for its lead drug, Vykat XR, and had 764 patients actively taking the medication by the end of September 2025.

Shares of the company were down more than 22% in Tuesday's after-market trading activity.

Price: 49.50, Change: -14.35, Percent Change: -22.47